Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: INCY stock price vs VNT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNT's multiple
Needs VNT P/E.
Implied fair value · at INCY's multiple
Needs INCY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INCY FY 2025 (ended Dec 31, 2025) · VNT FY 2025 (ended Dec 31, 2025).
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 4.62x · EV / EBITDA 13.50x
Capital structure 68% equity / 32% debt · EV / Revenue 1.98x · EV / EBITDA 8.68x
INCY carries the larger enterprise value at $23.73B against $6.10B; VNT trades on the lower EV / Revenue multiple (1.98x vs 4.62x); VNT on the lower EV / EBITDA (8.68x vs 13.50x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
INCYTE CORPORATION · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Vontier Corporation · implied price per share
Bear
$17.40
Base
$20.92
Bull
$27.16
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.29x
1.68x
Net debt / EBITDA
Leverage against operating earnings
-0.90x
2.28x
Cash and equivalents
Liquid reserves on the balance sheet
$3.10B
$492.20M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
INCY vs AMGN
GILEAD SCIENCES, INC.
INCY vs GILD
VERTEX PHARMACEUTICALS INC / MA
INCY vs VRTX
REGENERON PHARMACEUTICALS, INC.
INCY vs REGN
BIOGEN INC.
INCY vs BIIB
ROPER TECHNOLOGIES INC
INCY vs ROP
DOVER Corp
INCY vs DOV
BADGER METER INC
INCY vs BMI
ITRON, INC.
INCY vs ITRI
AMETEK INC/
INCY vs AME
$1.51B
$2.09B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
